SG185128A1 - Monitoring health and disease status using clonotype profiles - Google Patents

Info

Publication number

SG185128A1

SG185128A1 SG2012081527A SG2012081527A SG185128A1 SG 185128 A1 SG185128 A1 SG 185128A1 SG 2012081527 A SG2012081527 A SG 2012081527A SG 2012081527 A SG2012081527 A SG 2012081527A SG 185128 A1 SG185128 A1 SG 185128A1

Authority

SG

Singapore

Prior art keywords

disease

clonotypes

sample

cells

patient

Prior art date

2010-05-06

Links

• Espacenet
• Global Dossier
• Discuss

• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 390
• 201000010099 disease Diseases 0.000 title claims abstract description 379
• 238000012544 monitoring process Methods 0.000 title claims abstract description 50
• 230000036541 health Effects 0.000 title description 16
• 238000000034 method Methods 0.000 claims abstract description 333
• 206010028980 Neoplasm Diseases 0.000 claims abstract description 206
• 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 47
• 206010025323 Lymphomas Diseases 0.000 claims abstract description 25
• 208000032839 leukemia Diseases 0.000 claims abstract description 20
• 208000035475 disorder Diseases 0.000 claims abstract description 11
• 210000004027 cell Anatomy 0.000 claims description 273
• 238000012163 sequencing technique Methods 0.000 claims description 195
• 210000001744 T-lymphocyte Anatomy 0.000 claims description 131
• 210000003719 b-lymphocyte Anatomy 0.000 claims description 124
• 108020004414 DNA Proteins 0.000 claims description 118
• 210000001519 tissue Anatomy 0.000 claims description 104
• 150000007523 nucleic acids Chemical group 0.000 claims description 95
• 210000004698 lymphocyte Anatomy 0.000 claims description 86
• 102000039446 nucleic acids Human genes 0.000 claims description 84
• 108020004707 nucleic acids Proteins 0.000 claims description 84
• 230000008707 rearrangement Effects 0.000 claims description 70
• 108090000623 proteins and genes Proteins 0.000 claims description 47
• 108091028043 Nucleic acid sequence Proteins 0.000 claims description 37
• 230000014509 gene expression Effects 0.000 claims description 35
• 201000006417 multiple sclerosis Diseases 0.000 claims description 35
• 230000000392 somatic effect Effects 0.000 claims description 31
• 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 31
• 102000004169 proteins and genes Human genes 0.000 claims description 30
• 206010039073 rheumatoid arthritis Diseases 0.000 claims description 30
• 210000001185 bone marrow Anatomy 0.000 claims description 25
• 230000002596 correlated effect Effects 0.000 claims description 25
• 238000002255 vaccination Methods 0.000 claims description 21
• 210000005259 peripheral blood Anatomy 0.000 claims description 20
• 239000011886 peripheral blood Substances 0.000 claims description 20
• 230000000875 corresponding effect Effects 0.000 claims description 19
• 230000004044 response Effects 0.000 claims description 16
• 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 11
• 229960005486 vaccine Drugs 0.000 claims description 11
• 208000035473 Communicable disease Diseases 0.000 claims description 9
• 238000002955 isolation Methods 0.000 claims description 8
• 210000004976 peripheral blood cell Anatomy 0.000 claims description 8
• 230000004043 responsiveness Effects 0.000 claims description 8
• 210000003491 skin Anatomy 0.000 claims description 8
• 208000030289 Lymphoproliferative disease Diseases 0.000 claims description 5
• 210000003734 kidney Anatomy 0.000 claims description 5
• 238000002372 labelling Methods 0.000 claims description 5
• 210000003563 lymphoid tissue Anatomy 0.000 claims description 5
• 230000002062 proliferating effect Effects 0.000 claims description 5
• 210000001179 synovial fluid Anatomy 0.000 claims description 5
• 210000000601 blood cell Anatomy 0.000 claims 3
• 201000001268 lymphoproliferative syndrome Diseases 0.000 claims 3
• 125000003275 alpha amino acid group Chemical group 0.000 claims 2
• 210000002798 bone marrow cell Anatomy 0.000 claims 1
• 201000011510 cancer Diseases 0.000 abstract description 115
• 208000019420 lymphoid neoplasm Diseases 0.000 abstract description 24
• 238000003556 assay Methods 0.000 abstract description 19
• 238000003745 diagnosis Methods 0.000 abstract description 17
• 239000000090 biomarker Substances 0.000 abstract description 16
• 238000011161 development Methods 0.000 abstract description 7
• 238000004393 prognosis Methods 0.000 abstract description 7
• 206010065163 Clonal evolution Diseases 0.000 abstract description 6
• 238000001712 DNA sequencing Methods 0.000 abstract description 5
• 230000001976 improved effect Effects 0.000 abstract description 3
• 239000000523 sample Substances 0.000 description 311
• 239000000427 antigen Substances 0.000 description 184
• 108091007433 antigens Proteins 0.000 description 182
• 102000036639 antigens Human genes 0.000 description 182
• 230000003321 amplification Effects 0.000 description 141
• 238000003199 nucleic acid amplification method Methods 0.000 description 141
• 238000004422 calculation algorithm Methods 0.000 description 122
• 238000012360 testing method Methods 0.000 description 117
• 108091008874 T cell receptors Proteins 0.000 description 83
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 78
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 71
• 210000004369 blood Anatomy 0.000 description 54
• 239000008280 blood Substances 0.000 description 54
• 108091008875 B cell receptors Proteins 0.000 description 51
• 238000006243 chemical reaction Methods 0.000 description 50
• 238000001514 detection method Methods 0.000 description 50
• 230000035945 sensitivity Effects 0.000 description 50
• 238000011282 treatment Methods 0.000 description 46
• 239000003814 drug Substances 0.000 description 45
• 208000024891 symptom Diseases 0.000 description 45
• 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 40
• 229940079593 drug Drugs 0.000 description 38
• 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 37
• 239000002299 complementary DNA Substances 0.000 description 37
• 108091093088 Amplicon Proteins 0.000 description 32
• 230000009266 disease activity Effects 0.000 description 32
• 210000002865 immune cell Anatomy 0.000 description 30
• 239000002773 nucleotide Substances 0.000 description 30
• 125000003729 nucleotide group Chemical group 0.000 description 30
• 230000028993 immune response Effects 0.000 description 29
• 208000015181 infectious disease Diseases 0.000 description 29
• 235000018102 proteins Nutrition 0.000 description 29
• 206010002556 Ankylosing Spondylitis Diseases 0.000 description 28
• 230000000295 complement effect Effects 0.000 description 28
• 239000003550 marker Substances 0.000 description 28
• 239000007787 solid Substances 0.000 description 28
• 210000000987 immune system Anatomy 0.000 description 27
• 238000003753 real-time PCR Methods 0.000 description 27
• 238000004458 analytical method Methods 0.000 description 26
• 230000005945 translocation Effects 0.000 description 26
• 238000013459 approach Methods 0.000 description 24
• 108091008915 immune receptors Proteins 0.000 description 23
• 102000027596 immune receptors Human genes 0.000 description 22
• 230000002441 reversible effect Effects 0.000 description 22
• 206010020751 Hypersensitivity Diseases 0.000 description 21
• 230000035772 mutation Effects 0.000 description 21
• 244000052769 pathogen Species 0.000 description 21
• 230000001717 pathogenic effect Effects 0.000 description 21
• 239000000047 product Substances 0.000 description 21
• 230000001965 increasing effect Effects 0.000 description 20
• 238000002560 therapeutic procedure Methods 0.000 description 20
• 238000001574 biopsy Methods 0.000 description 19
• 108700028369 Alleles Proteins 0.000 description 18
• 239000003153 chemical reaction reagent Substances 0.000 description 18
• 238000000684 flow cytometry Methods 0.000 description 18
• 230000004054 inflammatory process Effects 0.000 description 18
• 210000001503 joint Anatomy 0.000 description 18
• 230000008569 process Effects 0.000 description 18
• 239000000463 material Substances 0.000 description 17
• 210000000056 organ Anatomy 0.000 description 17
• 206010069754 Acquired gene mutation Diseases 0.000 description 16
• 102000004127 Cytokines Human genes 0.000 description 16
• 108090000695 Cytokines Proteins 0.000 description 16
• 230000006378 damage Effects 0.000 description 16
• 102000018358 immunoglobulin Human genes 0.000 description 16
• 239000000203 mixture Substances 0.000 description 16
• 230000037439 somatic mutation Effects 0.000 description 16
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 15
• 206010061218 Inflammation Diseases 0.000 description 15
• 238000009396 hybridization Methods 0.000 description 15
• 238000011493 immune profiling Methods 0.000 description 15
• 239000011324 bead Substances 0.000 description 14
• 238000002509 fluorescent in situ hybridization Methods 0.000 description 14
• 238000004519 manufacturing process Methods 0.000 description 14
• 238000005259 measurement Methods 0.000 description 14
• 230000006798 recombination Effects 0.000 description 14
• 238000005215 recombination Methods 0.000 description 14
• 108010074051 C-Reactive Protein Proteins 0.000 description 13
• 102100032752 C-reactive protein Human genes 0.000 description 13
• 150000001413 amino acids Chemical group 0.000 description 13
• 230000008859 change Effects 0.000 description 13
• 238000005516 engineering process Methods 0.000 description 13
• 210000004881 tumor cell Anatomy 0.000 description 13
• 108020004705 Codon Proteins 0.000 description 12
• 238000002965 ELISA Methods 0.000 description 12
• 208000026935 allergic disease Diseases 0.000 description 12
• 239000002988 disease modifying antirheumatic drug Substances 0.000 description 12
• 206010016256 fatigue Diseases 0.000 description 12
• 238000002493 microarray Methods 0.000 description 12
• 108090000765 processed proteins & peptides Proteins 0.000 description 12
• 230000002829 reductive effect Effects 0.000 description 12
• 108091034117 Oligonucleotide Proteins 0.000 description 11
• 208000002193 Pain Diseases 0.000 description 11
• 230000004913 activation Effects 0.000 description 11
• 230000001154 acute effect Effects 0.000 description 11
• 230000008901 benefit Effects 0.000 description 11
• 230000006870 function Effects 0.000 description 11
• 108060003951 Immunoglobulin Proteins 0.000 description 10
• 108700042075 T-Cell Receptor Genes Proteins 0.000 description 10
• 206010003246 arthritis Diseases 0.000 description 10
• 230000001684 chronic effect Effects 0.000 description 10
• DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 10
• 230000007423 decrease Effects 0.000 description 10
• 238000002483 medication Methods 0.000 description 10
• 108700005091 Immunoglobulin Genes Proteins 0.000 description 9
• 210000001124 body fluid Anatomy 0.000 description 9
• 206010025135 lupus erythematosus Diseases 0.000 description 9
• 230000036407 pain Effects 0.000 description 9
• 238000003752 polymerase chain reaction Methods 0.000 description 9
• 238000000926 separation method Methods 0.000 description 9
• 230000004083 survival effect Effects 0.000 description 9
• 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 8
• 229920003266 Leaf® Polymers 0.000 description 8
• 210000005006 adaptive immune system Anatomy 0.000 description 8
• 239000013566 allergen Substances 0.000 description 8
• 230000001580 bacterial effect Effects 0.000 description 8
• 230000003247 decreasing effect Effects 0.000 description 8
• 238000009826 distribution Methods 0.000 description 8
• 230000000694 effects Effects 0.000 description 8
• 239000012634 fragment Substances 0.000 description 8
• 230000003993 interaction Effects 0.000 description 8
• 238000002595 magnetic resonance imaging Methods 0.000 description 8
• 238000007726 management method Methods 0.000 description 8
• 239000012071 phase Substances 0.000 description 8
• 241000894007 species Species 0.000 description 8
• 210000002700 urine Anatomy 0.000 description 8
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 7
• -1 IgH molecules Chemical class 0.000 description 7
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 7
• 238000002105 Southern blotting Methods 0.000 description 7
• 210000004556 brain Anatomy 0.000 description 7
• 150000001875 compounds Chemical class 0.000 description 7
• 238000010790 dilution Methods 0.000 description 7
• 239000012895 dilution Substances 0.000 description 7
• 238000013412 genome amplification Methods 0.000 description 7
• 230000009610 hypersensitivity Effects 0.000 description 7
• 230000008105 immune reaction Effects 0.000 description 7
• 239000012678 infectious agent Substances 0.000 description 7
• 210000000265 leukocyte Anatomy 0.000 description 7
• 230000001404 mediated effect Effects 0.000 description 7
• 229960000485 methotrexate Drugs 0.000 description 7
• 230000008816 organ damage Effects 0.000 description 7
• 230000001575 pathological effect Effects 0.000 description 7
• 238000003786 synthesis reaction Methods 0.000 description 7
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 6
• 108010036949 Cyclosporine Proteins 0.000 description 6
• 241000701022 Cytomegalovirus Species 0.000 description 6
• 238000000018 DNA microarray Methods 0.000 description 6
• 229940123907 Disease modifying antirheumatic drug Drugs 0.000 description 6
• UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 6
• 238000000636 Northern blotting Methods 0.000 description 6
• 108091005461 Nucleic proteins Proteins 0.000 description 6
• 238000000137 annealing Methods 0.000 description 6
• 239000003435 antirheumatic agent Substances 0.000 description 6
• LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 6
• 230000015572 biosynthetic process Effects 0.000 description 6
• 150000001720 carbohydrates Chemical class 0.000 description 6
• 235000014633 carbohydrates Nutrition 0.000 description 6
• 230000002759 chromosomal effect Effects 0.000 description 6
• 230000000052 comparative effect Effects 0.000 description 6
• 230000018109 developmental process Effects 0.000 description 6
• 238000010195 expression analysis Methods 0.000 description 6
• 238000001502 gel electrophoresis Methods 0.000 description 6
• 238000012268 genome sequencing Methods 0.000 description 6
• 210000002216 heart Anatomy 0.000 description 6
• 230000003053 immunization Effects 0.000 description 6
• 238000002649 immunization Methods 0.000 description 6
• 238000003364 immunohistochemistry Methods 0.000 description 6
• 238000007901 in situ hybridization Methods 0.000 description 6
• 238000000338 in vitro Methods 0.000 description 6
• 230000003902 lesion Effects 0.000 description 6
• 150000002632 lipids Chemical class 0.000 description 6
• 210000004185 liver Anatomy 0.000 description 6
• 210000004072 lung Anatomy 0.000 description 6
• 238000007403 mPCR Methods 0.000 description 6
• 238000013507 mapping Methods 0.000 description 6
• 238000010208 microarray analysis Methods 0.000 description 6
• 210000005036 nerve Anatomy 0.000 description 6
• 102000005962 receptors Human genes 0.000 description 6
• 108020003175 receptors Proteins 0.000 description 6
• 238000012216 screening Methods 0.000 description 6
• 238000004062 sedimentation Methods 0.000 description 6
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
• 229960001940 sulfasalazine Drugs 0.000 description 6
• NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 6
• NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 6
• 238000002054 transplantation Methods 0.000 description 6
• WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 5
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 5
• 206010002198 Anaphylactic reaction Diseases 0.000 description 5
• 102100027207 CD27 antigen Human genes 0.000 description 5
• 208000010201 Exanthema Diseases 0.000 description 5
• 208000009329 Graft vs Host Disease Diseases 0.000 description 5
• 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 5
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 5
• 206010052779 Transplant rejections Diseases 0.000 description 5
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
• 230000036783 anaphylactic response Effects 0.000 description 5
• 208000003455 anaphylaxis Diseases 0.000 description 5
• 230000000890 antigenic effect Effects 0.000 description 5
• 208000006673 asthma Diseases 0.000 description 5
• 230000001363 autoimmune Effects 0.000 description 5
• 229960002170 azathioprine Drugs 0.000 description 5
• 239000002458 cell surface marker Substances 0.000 description 5
• 229940109239 creatinine Drugs 0.000 description 5
• 230000034994 death Effects 0.000 description 5
• 231100000517 death Toxicity 0.000 description 5
• 208000037765 diseases and disorders Diseases 0.000 description 5
• 239000000839 emulsion Substances 0.000 description 5
• 210000003743 erythrocyte Anatomy 0.000 description 5
• 201000005884 exanthem Diseases 0.000 description 5
• 210000001508 eye Anatomy 0.000 description 5
• 239000007850 fluorescent dye Substances 0.000 description 5
• 208000024908 graft versus host disease Diseases 0.000 description 5
• 238000003384 imaging method Methods 0.000 description 5
• 230000002757 inflammatory effect Effects 0.000 description 5
• 206010022000 influenza Diseases 0.000 description 5
• 230000007774 longterm Effects 0.000 description 5
• 235000019689 luncheon sausage Nutrition 0.000 description 5
• 230000007246 mechanism Effects 0.000 description 5
• 102000004196 processed proteins & peptides Human genes 0.000 description 5
• 206010037844 rash Diseases 0.000 description 5
• 230000009467 reduction Effects 0.000 description 5
• 238000011160 research Methods 0.000 description 5
• 201000005671 spondyloarthropathy Diseases 0.000 description 5
• 230000000638 stimulation Effects 0.000 description 5
• 238000001262 western blot Methods 0.000 description 5
• 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 4
• 208000005443 Circulating Neoplastic Cells Diseases 0.000 description 4
• VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 4
• 206010012735 Diarrhoea Diseases 0.000 description 4
• 206010016946 Food allergy Diseases 0.000 description 4
• 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 4
• 206010035226 Plasma cell myeloma Diseases 0.000 description 4
• 208000006045 Spondylarthropathies Diseases 0.000 description 4
• 102000004903 Troponin Human genes 0.000 description 4
• 108090001027 Troponin Proteins 0.000 description 4
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
• 230000032683 aging Effects 0.000 description 4
• 230000007815 allergy Effects 0.000 description 4
• 230000005784 autoimmunity Effects 0.000 description 4
• 238000009534 blood test Methods 0.000 description 4
• 239000010839 body fluid Substances 0.000 description 4
• 239000000872 buffer Substances 0.000 description 4
• 239000003795 chemical substances by application Substances 0.000 description 4
• 238000007796 conventional method Methods 0.000 description 4
• 230000004927 fusion Effects 0.000 description 4
• 210000004602 germ cell Anatomy 0.000 description 4
• 208000019622 heart disease Diseases 0.000 description 4
• XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 4
• 229960004171 hydroxychloroquine Drugs 0.000 description 4
• 230000001506 immunosuppresive effect Effects 0.000 description 4
• 239000003018 immunosuppressive agent Substances 0.000 description 4
• 230000003834 intracellular effect Effects 0.000 description 4
• 210000002414 leg Anatomy 0.000 description 4
• 230000003211 malignant effect Effects 0.000 description 4
• 229960001639 penicillamine Drugs 0.000 description 4
• 208000005987 polymyositis Diseases 0.000 description 4
• 230000009257 reactivity Effects 0.000 description 4
• 239000000243 solution Substances 0.000 description 4
• 210000000278 spinal cord Anatomy 0.000 description 4
• 230000001225 therapeutic effect Effects 0.000 description 4
• RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 3
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 3
• 208000008822 Ankylosis Diseases 0.000 description 3
• 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 3
• 208000006820 Arthralgia Diseases 0.000 description 3
• 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 3
• 108091012583 BCL2 Proteins 0.000 description 3
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 3
• 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 3
• 208000033222 Biliary cirrhosis primary Diseases 0.000 description 3
• 208000011691 Burkitt lymphomas Diseases 0.000 description 3
• 208000017667 Chronic Disease Diseases 0.000 description 3
• 208000015943 Coeliac disease Diseases 0.000 description 3
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
• 229930105110 Cyclosporin A Natural products 0.000 description 3
• 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
• 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
• 102000004190 Enzymes Human genes 0.000 description 3
• 108090000790 Enzymes Proteins 0.000 description 3
• 108010008165 Etanercept Proteins 0.000 description 3
• 208000004262 Food Hypersensitivity Diseases 0.000 description 3
• 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 3
• 206010062016 Immunosuppression Diseases 0.000 description 3
• 108010002350 Interleukin-2 Proteins 0.000 description 3
• 208000034578 Multiple myelomas Diseases 0.000 description 3
• 208000007101 Muscle Cramp Diseases 0.000 description 3
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 3
• 102000003729 Neprilysin Human genes 0.000 description 3
• 108090000028 Neprilysin Proteins 0.000 description 3
• 108020005187 Oligonucleotide Probes Proteins 0.000 description 3
• 208000012654 Primary biliary cholangitis Diseases 0.000 description 3
• 208000033759 Prolymphocytic T-Cell Leukemia Diseases 0.000 description 3
• 206010039085 Rhinitis allergic Diseases 0.000 description 3
• 206010039710 Scleroderma Diseases 0.000 description 3
• 208000021386 Sjogren Syndrome Diseases 0.000 description 3
• 208000026651 T-cell prolymphocytic leukemia Diseases 0.000 description 3
• 101150002618 TCRP gene Proteins 0.000 description 3
• 108010006785 Taq Polymerase Proteins 0.000 description 3
• 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 3
• 241000700605 Viruses Species 0.000 description 3
• 230000002159 abnormal effect Effects 0.000 description 3
• 230000003044 adaptive effect Effects 0.000 description 3
• 238000007792 addition Methods 0.000 description 3
• 201000010105 allergic rhinitis Diseases 0.000 description 3
• 229940035676 analgesics Drugs 0.000 description 3
• 239000000730 antalgic agent Substances 0.000 description 3
• 239000002260 anti-inflammatory agent Substances 0.000 description 3
• 229940124599 anti-inflammatory drug Drugs 0.000 description 3
• 230000037429 base substitution Effects 0.000 description 3
• 210000003651 basophil Anatomy 0.000 description 3
• 229960000074 biopharmaceutical Drugs 0.000 description 3
• 238000004820 blood count Methods 0.000 description 3
• 238000010804 cDNA synthesis Methods 0.000 description 3
• 239000002771 cell marker Substances 0.000 description 3
• 210000003169 central nervous system Anatomy 0.000 description 3
• 229960001265 ciclosporin Drugs 0.000 description 3
• 239000003246 corticosteroid Substances 0.000 description 3
• 238000004163 cytometry Methods 0.000 description 3
• 238000012217 deletion Methods 0.000 description 3
• 230000037430 deletion Effects 0.000 description 3
• 230000001419 dependent effect Effects 0.000 description 3
• 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 3
• 238000001962 electrophoresis Methods 0.000 description 3
• 238000002474 experimental method Methods 0.000 description 3
• 239000012530 fluid Substances 0.000 description 3
• 201000003444 follicular lymphoma Diseases 0.000 description 3
• 235000020932 food allergy Nutrition 0.000 description 3
• 239000000499 gel Substances 0.000 description 3
• 230000012010 growth Effects 0.000 description 3
• 210000003630 histaminocyte Anatomy 0.000 description 3
• 230000001900 immune effect Effects 0.000 description 3
• 230000000899 immune system response Effects 0.000 description 3
• 238000010166 immunofluorescence Methods 0.000 description 3
• 229940072221 immunoglobulins Drugs 0.000 description 3
• 230000000415 inactivating effect Effects 0.000 description 3
• 238000010348 incorporation Methods 0.000 description 3
• 108020004999 messenger RNA Proteins 0.000 description 3
• 239000003147 molecular marker Substances 0.000 description 3
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
• 239000002751 oligonucleotide probe Substances 0.000 description 3
• 238000005457 optimization Methods 0.000 description 3
• 238000004806 packaging method and process Methods 0.000 description 3
• 239000013610 patient sample Substances 0.000 description 3
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
• 238000005191 phase separation Methods 0.000 description 3
• 210000002381 plasma Anatomy 0.000 description 3
• 238000011896 sensitive detection Methods 0.000 description 3
• 238000010561 standard procedure Methods 0.000 description 3
• 150000003431 steroids Chemical class 0.000 description 3
• 230000009885 systemic effect Effects 0.000 description 3
• 230000008685 targeting Effects 0.000 description 3
• 229940124597 therapeutic agent Drugs 0.000 description 3
• 230000001988 toxicity Effects 0.000 description 3
• 231100000419 toxicity Toxicity 0.000 description 3
• 239000000439 tumor marker Substances 0.000 description 3
• 208000027930 type IV hypersensitivity disease Diseases 0.000 description 3
• 238000002604 ultrasonography Methods 0.000 description 3
• 241001430294 unidentified retrovirus Species 0.000 description 3
• 230000008673 vomiting Effects 0.000 description 3
• 208000016261 weight loss Diseases 0.000 description 3
• 230000004580 weight loss Effects 0.000 description 3
• BSDCIRGNJKZPFV-GWOFURMSSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-(2,5,6-trichlorobenzimidazol-1-yl)oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=CC(Cl)=C(Cl)C=C2N=C1Cl BSDCIRGNJKZPFV-GWOFURMSSA-N 0.000 description 2
• JVJFIQYAHPMBBX-UHFFFAOYSA-N 4-hydroxynonenal Chemical compound CCCCCC(O)C=CC=O JVJFIQYAHPMBBX-UHFFFAOYSA-N 0.000 description 2
• 208000024827 Alzheimer disease Diseases 0.000 description 2
• 206010003827 Autoimmune hepatitis Diseases 0.000 description 2
• 101150076489 B gene Proteins 0.000 description 2
• 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 description 2
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
• 208000003950 B-cell lymphoma Diseases 0.000 description 2
• 208000032568 B-cell prolymphocytic leukaemia Diseases 0.000 description 2
• 208000008035 Back Pain Diseases 0.000 description 2
• KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 2
• 235000017166 Bambusa arundinacea Nutrition 0.000 description 2
• 235000017491 Bambusa tulda Nutrition 0.000 description 2
• 241001330002 Bambuseae Species 0.000 description 2
• 208000023328 Basedow disease Diseases 0.000 description 2
• 201000004569 Blindness Diseases 0.000 description 2
• 206010006187 Breast cancer Diseases 0.000 description 2
• 208000026310 Breast neoplasm Diseases 0.000 description 2
• 208000023611 Burkitt leukaemia Diseases 0.000 description 2
• 208000024172 Cardiovascular disease Diseases 0.000 description 2
• 206010008342 Cervix carcinoma Diseases 0.000 description 2
• 108010012236 Chemokines Proteins 0.000 description 2
• 102000019034 Chemokines Human genes 0.000 description 2
• 208000000094 Chronic Pain Diseases 0.000 description 2
• XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 2
• 208000019505 Deglutition disease Diseases 0.000 description 2
• 206010012438 Dermatitis atopic Diseases 0.000 description 2
• 206010013700 Drug hypersensitivity Diseases 0.000 description 2
• 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 2
• 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 2
• 108010072051 Glatiramer Acetate Proteins 0.000 description 2
• 208000015023 Graves' disease Diseases 0.000 description 2
• 101000980756 Homo sapiens G1/S-specific cyclin-D1 Proteins 0.000 description 2
• 101000763322 Homo sapiens M1-specific T cell receptor beta chain Proteins 0.000 description 2
• 101000763321 Homo sapiens T cell receptor beta chain MC.7.G5 Proteins 0.000 description 2
• 102000012745 Immunoglobulin Subunits Human genes 0.000 description 2
• 108010079585 Immunoglobulin Subunits Proteins 0.000 description 2
• 102100034343 Integrase Human genes 0.000 description 2
• 108010005716 Interferon beta-1a Proteins 0.000 description 2
• 108010002352 Interleukin-1 Proteins 0.000 description 2
• 102000000589 Interleukin-1 Human genes 0.000 description 2
• 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 2
• 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 2
• 102000004889 Interleukin-6 Human genes 0.000 description 2
• 108090001005 Interleukin-6 Proteins 0.000 description 2
• 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 2
• 208000006404 Large Granular Lymphocytic Leukemia Diseases 0.000 description 2
• 102100026964 M1-specific T cell receptor beta chain Human genes 0.000 description 2
• 201000003791 MALT lymphoma Diseases 0.000 description 2
• 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 2
• 241001465754 Metazoa Species 0.000 description 2
• 208000003250 Mixed connective tissue disease Diseases 0.000 description 2
• 208000010428 Muscle Weakness Diseases 0.000 description 2
• 206010028372 Muscular weakness Diseases 0.000 description 2
• 208000000112 Myalgia Diseases 0.000 description 2
• 206010028813 Nausea Diseases 0.000 description 2
• 206010029461 Nodal marginal zone B-cell lymphomas Diseases 0.000 description 2
• 206010034277 Pemphigoid Diseases 0.000 description 2
• 208000031845 Pernicious anaemia Diseases 0.000 description 2
• 201000007100 Pharyngitis Diseases 0.000 description 2
• 235000015334 Phyllostachys viridis Nutrition 0.000 description 2
• 206010035664 Pneumonia Diseases 0.000 description 2
• 208000035416 Prolymphocytic B-Cell Leukemia Diseases 0.000 description 2
• 208000003251 Pruritus Diseases 0.000 description 2
• 206010068513 Pulmonary renal syndrome Diseases 0.000 description 2
• 206010037660 Pyrexia Diseases 0.000 description 2
• 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
• 208000007660 Residual Neoplasm Diseases 0.000 description 2
• 208000005392 Spasm Diseases 0.000 description 2
• 230000005867 T cell response Effects 0.000 description 2
• 201000008717 T-cell large granular lymphocyte leukemia Diseases 0.000 description 2
• 206010042971 T-cell lymphoma Diseases 0.000 description 2
• 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
• 102000011923 Thyrotropin Human genes 0.000 description 2
• 108010061174 Thyrotropin Proteins 0.000 description 2
• 206010044565 Tremor Diseases 0.000 description 2
• 102100040247 Tumor necrosis factor Human genes 0.000 description 2
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
• 206010047115 Vasculitis Diseases 0.000 description 2
• 206010047700 Vomiting Diseases 0.000 description 2
• PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 2
• 230000001594 aberrant effect Effects 0.000 description 2
• 230000001133 acceleration Effects 0.000 description 2
• 239000002253 acid Substances 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 229960002964 adalimumab Drugs 0.000 description 2
• 230000004721 adaptive immunity Effects 0.000 description 2
• 230000002411 adverse Effects 0.000 description 2
• 208000030961 allergic reaction Diseases 0.000 description 2
• 230000003466 anti-cipated effect Effects 0.000 description 2
• 229940121363 anti-inflammatory agent Drugs 0.000 description 2
• 230000003460 anti-nuclear Effects 0.000 description 2
• 230000009831 antigen interaction Effects 0.000 description 2
• 210000000612 antigen-presenting cell Anatomy 0.000 description 2
• 238000003491 array Methods 0.000 description 2
• 201000008937 atopic dermatitis Diseases 0.000 description 2
• 239000011425 bamboo Substances 0.000 description 2
• 230000004888 barrier function Effects 0.000 description 2
• 230000006399 behavior Effects 0.000 description 2
• 239000003124 biologic agent Substances 0.000 description 2
• 208000002352 blister Diseases 0.000 description 2
• 230000036772 blood pressure Effects 0.000 description 2
• 210000000988 bone and bone Anatomy 0.000 description 2
• 230000004663 cell proliferation Effects 0.000 description 2
• 210000002939 cerumen Anatomy 0.000 description 2
• 201000010881 cervical cancer Diseases 0.000 description 2
• 238000002512 chemotherapy Methods 0.000 description 2
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
• 210000000349 chromosome Anatomy 0.000 description 2
• 208000029742 colonic neoplasm Diseases 0.000 description 2
• 238000002591 computed tomography Methods 0.000 description 2
• 239000000470 constituent Substances 0.000 description 2
• 229960001334 corticosteroids Drugs 0.000 description 2
• 230000009260 cross reactivity Effects 0.000 description 2
• 230000001351 cycling effect Effects 0.000 description 2
• 229960004397 cyclophosphamide Drugs 0.000 description 2
• 230000001086 cytosolic effect Effects 0.000 description 2
• 231100000433 cytotoxic Toxicity 0.000 description 2
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
• 230000001472 cytotoxic effect Effects 0.000 description 2
• 206010061428 decreased appetite Diseases 0.000 description 2
• 238000004925 denaturation Methods 0.000 description 2
• 230000036425 denaturation Effects 0.000 description 2
• 230000008021 deposition Effects 0.000 description 2
• 238000013461 design Methods 0.000 description 2
• 206010012601 diabetes mellitus Diseases 0.000 description 2
• 238000007847 digital PCR Methods 0.000 description 2
• 239000000428 dust Substances 0.000 description 2
• 230000008030 elimination Effects 0.000 description 2
• 238000003379 elimination reaction Methods 0.000 description 2
• 229960000403 etanercept Drugs 0.000 description 2
• 238000011156 evaluation Methods 0.000 description 2
• 238000000605 extraction Methods 0.000 description 2
• 235000013305 food Nutrition 0.000 description 2
• 230000002068 genetic effect Effects 0.000 description 2
• 239000011521 glass Substances 0.000 description 2
• 150000002343 gold Chemical class 0.000 description 2
• 150000002344 gold compounds Chemical class 0.000 description 2
• 210000005003 heart tissue Anatomy 0.000 description 2
• 210000002443 helper t lymphocyte Anatomy 0.000 description 2
• 208000002672 hepatitis B Diseases 0.000 description 2
• 230000002163 immunogen Effects 0.000 description 2
• 238000013394 immunophenotyping Methods 0.000 description 2
• 229960003444 immunosuppressant agent Drugs 0.000 description 2
• 229940125721 immunosuppressive agent Drugs 0.000 description 2
• 238000009169 immunotherapy Methods 0.000 description 2
• 230000006872 improvement Effects 0.000 description 2
• 238000001727 in vivo Methods 0.000 description 2
• CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
• 230000001939 inductive effect Effects 0.000 description 2
• 229960000598 infliximab Drugs 0.000 description 2
• 230000002401 inhibitory effect Effects 0.000 description 2
• 230000000977 initiatory effect Effects 0.000 description 2
• 238000002347 injection Methods 0.000 description 2
• 239000007924 injection Substances 0.000 description 2
• 229940100601 interleukin-6 Drugs 0.000 description 2
• 238000007852 inverse PCR Methods 0.000 description 2
• 208000018937 joint inflammation Diseases 0.000 description 2
• 238000011862 kidney biopsy Methods 0.000 description 2
• 229960000681 leflunomide Drugs 0.000 description 2
• VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 2
• 239000007791 liquid phase Substances 0.000 description 2
• 238000009593 lumbar puncture Methods 0.000 description 2
• 210000002751 lymph Anatomy 0.000 description 2
• 210000001165 lymph node Anatomy 0.000 description 2
• 239000000693 micelle Substances 0.000 description 2
• HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 2
• 206010063344 microscopic polyangiitis Diseases 0.000 description 2
• 230000005012 migration Effects 0.000 description 2
• 238000013508 migration Methods 0.000 description 2
• 230000003278 mimic effect Effects 0.000 description 2
• DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 description 2
• 229960004023 minocycline Drugs 0.000 description 2
• KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
• 230000004048 modification Effects 0.000 description 2
• 238000012986 modification Methods 0.000 description 2
• 230000008693 nausea Effects 0.000 description 2
• 230000000926 neurological effect Effects 0.000 description 2
• 238000007481 next generation sequencing Methods 0.000 description 2
• 229910052757 nitrogen Inorganic materials 0.000 description 2
• 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
• 231100000862 numbness Toxicity 0.000 description 2
• 230000002018 overexpression Effects 0.000 description 2
• 210000000496 pancreas Anatomy 0.000 description 2
• 229960005489 paracetamol Drugs 0.000 description 2
• 230000007170 pathology Effects 0.000 description 2
• 210000004197 pelvis Anatomy 0.000 description 2
• 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
• 238000012123 point-of-care testing Methods 0.000 description 2
• 238000006116 polymerization reaction Methods 0.000 description 2
• 230000001124 posttranscriptional effect Effects 0.000 description 2
• 230000003389 potentiating effect Effects 0.000 description 2
• 210000004909 pre-ejaculatory fluid Anatomy 0.000 description 2
• 239000002243 precursor Substances 0.000 description 2
• 238000002360 preparation method Methods 0.000 description 2
• 210000002307 prostate Anatomy 0.000 description 2
• 230000005855 radiation Effects 0.000 description 2
• 238000001959 radiotherapy Methods 0.000 description 2
• 238000010839 reverse transcription Methods 0.000 description 2
• 210000003705 ribosome Anatomy 0.000 description 2
• 229960004641 rituximab Drugs 0.000 description 2
• 210000003131 sacroiliac joint Anatomy 0.000 description 2
• 238000005070 sampling Methods 0.000 description 2
• 230000001932 seasonal effect Effects 0.000 description 2
• 230000028327 secretion Effects 0.000 description 2
• 231100000046 skin rash Toxicity 0.000 description 2
• 239000007790 solid phase Substances 0.000 description 2
• 238000010186 staining Methods 0.000 description 2
• 238000007447 staining method Methods 0.000 description 2
• 239000000126 substance Substances 0.000 description 2
• 230000000153 supplemental effect Effects 0.000 description 2
• 208000011580 syndromic disease Diseases 0.000 description 2
• 201000004595 synovitis Diseases 0.000 description 2
• 230000002194 synthesizing effect Effects 0.000 description 2
• 210000001541 thymus gland Anatomy 0.000 description 2
• 230000000451 tissue damage Effects 0.000 description 2
• 231100000827 tissue damage Toxicity 0.000 description 2
• XFYDIVBRZNQMJC-UHFFFAOYSA-N tizanidine Chemical compound ClC=1C=CC2=NSN=C2C=1NC1=NCCN1 XFYDIVBRZNQMJC-UHFFFAOYSA-N 0.000 description 2
• 230000009466 transformation Effects 0.000 description 2
• 230000004614 tumor growth Effects 0.000 description 2
• 229940079023 tysabri Drugs 0.000 description 2
• 238000011144 upstream manufacturing Methods 0.000 description 2
• 238000002562 urinalysis Methods 0.000 description 2
• 230000003612 virological effect Effects 0.000 description 2
• 230000004393 visual impairment Effects 0.000 description 2
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
• 230000004584 weight gain Effects 0.000 description 2
• 235000019786 weight gain Nutrition 0.000 description 2
• GIANIJCPTPUNBA-QMMMGPOBSA-N (2s)-3-(4-hydroxyphenyl)-2-nitramidopropanoic acid Chemical compound [O-][N+](=O)N[C@H](C(=O)O)CC1=CC=C(O)C=C1 GIANIJCPTPUNBA-QMMMGPOBSA-N 0.000 description 1
• SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
• 208000030507 AIDS Diseases 0.000 description 1
• 208000004998 Abdominal Pain Diseases 0.000 description 1
• 208000000187 Abnormal Reflex Diseases 0.000 description 1
• 206010000171 Abnormal reflexes Diseases 0.000 description 1
• 206010000830 Acute leukaemia Diseases 0.000 description 1
• 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
• 208000026872 Addison Disease Diseases 0.000 description 1
• 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 1
• 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
• 201000004384 Alopecia Diseases 0.000 description 1
• 206010001935 American trypanosomiasis Diseases 0.000 description 1
• 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 1
• 241001156002 Anthonomus pomorum Species 0.000 description 1
• 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
• 206010002921 Aortitis Diseases 0.000 description 1
• 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 description 1
• 102100021631 B-cell lymphoma 6 protein Human genes 0.000 description 1
• 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
• 108700020463 BRCA1 Proteins 0.000 description 1
• 102000036365 BRCA1 Human genes 0.000 description 1
• 101150072950 BRCA1 gene Proteins 0.000 description 1
• 108700020462 BRCA2 Proteins 0.000 description 1
• 102000052609 BRCA2 Human genes 0.000 description 1
• 241000894006 Bacteria Species 0.000 description 1
• 208000035143 Bacterial infection Diseases 0.000 description 1
• 208000035462 Biphenotypic Acute Leukemia Diseases 0.000 description 1
• 206010051779 Bone marrow toxicity Diseases 0.000 description 1
• 101150008921 Brca2 gene Proteins 0.000 description 1
• 206010067982 Butterfly rash Diseases 0.000 description 1
• 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
• 201000004085 CLL/SLL Diseases 0.000 description 1
• 101150071146 COX2 gene Proteins 0.000 description 1
• 101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 description 1
• 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 101710132601 Capsid protein Proteins 0.000 description 1
• 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
• 206010050337 Cerumen impaction Diseases 0.000 description 1
• 208000024699 Chagas disease Diseases 0.000 description 1
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
• 206010009192 Circulatory collapse Diseases 0.000 description 1
• 241000193163 Clostridioides difficile Species 0.000 description 1
• 206010009944 Colon cancer Diseases 0.000 description 1
• 102100030886 Complement receptor type 1 Human genes 0.000 description 1
• 206010010741 Conjunctivitis Diseases 0.000 description 1
• 206010010774 Constipation Diseases 0.000 description 1
• 206010010904 Convulsion Diseases 0.000 description 1
• 241000711573 Coronaviridae Species 0.000 description 1
• 102000053602 DNA Human genes 0.000 description 1
• 102000012410 DNA Ligases Human genes 0.000 description 1
• 108010061982 DNA Ligases Proteins 0.000 description 1
• 230000004544 DNA amplification Effects 0.000 description 1
• 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
• 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
• 206010011878 Deafness Diseases 0.000 description 1
• 241000725619 Dengue virus Species 0.000 description 1
• 201000004624 Dermatitis Diseases 0.000 description 1
• 206010012434 Dermatitis allergic Diseases 0.000 description 1
• 206010012442 Dermatitis contact Diseases 0.000 description 1
• 208000003164 Diplopia Diseases 0.000 description 1
• 206010061818 Disease progression Diseases 0.000 description 1
• 206010061819 Disease recurrence Diseases 0.000 description 1
• 208000000059 Dyspnea Diseases 0.000 description 1
• 206010013975 Dyspnoeas Diseases 0.000 description 1
• 238000012286 ELISA Assay Methods 0.000 description 1
• 102100025137 Early activation antigen CD69 Human genes 0.000 description 1
• 206010015150 Erythema Diseases 0.000 description 1
• 206010061850 Extranodal marginal zone B-cell lymphoma (MALT type) Diseases 0.000 description 1
• 206010015958 Eye pain Diseases 0.000 description 1
• 206010016059 Facial pain Diseases 0.000 description 1
• 241000282326 Felis catus Species 0.000 description 1
• 102000008857 Ferritin Human genes 0.000 description 1
• 108050000784 Ferritin Proteins 0.000 description 1
• 238000008416 Ferritin Methods 0.000 description 1
• 206010017533 Fungal infection Diseases 0.000 description 1
• 229910052688 Gadolinium Inorganic materials 0.000 description 1
• 206010017577 Gait disturbance Diseases 0.000 description 1
• 206010018378 Glomerulonephritis rapidly progressive Diseases 0.000 description 1
• 108010068370 Glutens Proteins 0.000 description 1
• 206010018498 Goitre Diseases 0.000 description 1
• 208000024869 Goodpasture syndrome Diseases 0.000 description 1
• 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
• 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
• 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
• 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
• 208000018565 Hemochromatosis Diseases 0.000 description 1
• 102000001554 Hemoglobins Human genes 0.000 description 1
• 108010054147 Hemoglobins Proteins 0.000 description 1
• 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
• 241000711549 Hepacivirus C Species 0.000 description 1
• 241000700721 Hepatitis B virus Species 0.000 description 1
• 108700039791 Hepatitis C virus nucleocapsid Proteins 0.000 description 1
• 206010019842 Hepatomegaly Diseases 0.000 description 1
• 108091027305 Heteroduplex Proteins 0.000 description 1
• 102000029746 Histidine-tRNA Ligase Human genes 0.000 description 1
• 108700016229 Histidine-tRNA ligases Proteins 0.000 description 1
• 108010033040 Histones Proteins 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101000971234 Homo sapiens B-cell lymphoma 6 protein Proteins 0.000 description 1
• 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
• 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 1
• 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 1
• 101000727061 Homo sapiens Complement receptor type 1 Proteins 0.000 description 1
• 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 1
• 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
• 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
• 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
• 101000972485 Homo sapiens Lupus La protein Proteins 0.000 description 1
• 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
• 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
• 241000341655 Human papillomavirus type 16 Species 0.000 description 1
• 208000008454 Hyperhidrosis Diseases 0.000 description 1
• 208000004044 Hypesthesia Diseases 0.000 description 1
• HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
• 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
• 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
• 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
• 206010021639 Incontinence Diseases 0.000 description 1
• 206010062717 Increased upper airway secretion Diseases 0.000 description 1
• 108010005714 Interferon beta-1b Proteins 0.000 description 1
• 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 1
• 108010050904 Interferons Proteins 0.000 description 1
• 102000014150 Interferons Human genes 0.000 description 1
• 208000005615 Interstitial Cystitis Diseases 0.000 description 1
• 206010022941 Iridocyclitis Diseases 0.000 description 1
• 208000000209 Isaacs syndrome Diseases 0.000 description 1
• 206010023126 Jaundice Diseases 0.000 description 1
• 206010023198 Joint ankylosis Diseases 0.000 description 1
• 206010023230 Joint stiffness Diseases 0.000 description 1
• 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
• 238000008214 LDL Cholesterol Methods 0.000 description 1
• 108010063045 Lactoferrin Proteins 0.000 description 1
• 102100032241 Lactotransferrin Human genes 0.000 description 1
• 206010023791 Large granular lymphocytosis Diseases 0.000 description 1
• 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 1
• 208000032420 Latent Infection Diseases 0.000 description 1
• 241000713666 Lentivirus Species 0.000 description 1
• 102000001109 Leukocyte L1 Antigen Complex Human genes 0.000 description 1
• 108010069316 Leukocyte L1 Antigen Complex Proteins 0.000 description 1
• NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
• 102000003960 Ligases Human genes 0.000 description 1
• 108090000364 Ligases Proteins 0.000 description 1
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
• 102100022742 Lupus La protein Human genes 0.000 description 1
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
• 102000043129 MHC class I family Human genes 0.000 description 1
• 108091054437 MHC class I family Proteins 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 description 1
• RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
• 108060004795 Methyltransferase Proteins 0.000 description 1
• 108700011259 MicroRNAs Proteins 0.000 description 1
• 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
• 108020005196 Mitochondrial DNA Proteins 0.000 description 1
• 241000699666 Mus <mouse, genus> Species 0.000 description 1
• 208000008238 Muscle Spasticity Diseases 0.000 description 1
• 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
• 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
• 208000031888 Mycoses Diseases 0.000 description 1
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
• CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
• 208000028389 Nerve injury Diseases 0.000 description 1
• 208000012902 Nervous system disease Diseases 0.000 description 1
• 206010029216 Nervousness Diseases 0.000 description 1
• 208000011644 Neurologic Gait disease Diseases 0.000 description 1
• 206010072359 Neuromyotonia Diseases 0.000 description 1
• 206010029803 Nosocomial infection Diseases 0.000 description 1
• 102100030569 Nuclear receptor corepressor 2 Human genes 0.000 description 1
• 101710153660 Nuclear receptor corepressor 2 Proteins 0.000 description 1
• 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
• 208000008589 Obesity Diseases 0.000 description 1
• 206010061137 Ocular toxicity Diseases 0.000 description 1
• 208000006187 Onycholysis Diseases 0.000 description 1
• 206010031009 Oral pain Diseases 0.000 description 1
• 206010053159 Organ failure Diseases 0.000 description 1
• 206010068319 Oropharyngeal pain Diseases 0.000 description 1
• 102100034574 P protein Human genes 0.000 description 1
• 101710181008 P protein Proteins 0.000 description 1
• 238000012408 PCR amplification Methods 0.000 description 1
• 101150000187 PTGS2 gene Proteins 0.000 description 1
• 206010033546 Pallor Diseases 0.000 description 1
• 206010033661 Pancytopenia Diseases 0.000 description 1
• 208000031816 Pathologic Dilatation Diseases 0.000 description 1
• 208000037273 Pathologic Processes Diseases 0.000 description 1
• 201000011152 Pemphigus Diseases 0.000 description 1
• 241000721454 Pemphigus Species 0.000 description 1
• 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 1
• 101710177166 Phosphoprotein Proteins 0.000 description 1
• 206010034960 Photophobia Diseases 0.000 description 1
• ZYFVNVRFVHJEIU-UHFFFAOYSA-N PicoGreen Chemical compound CN(C)CCCN(CCCN(C)C)C1=CC(=CC2=[N+](C3=CC=CC=C3S2)C)C2=CC=CC=C2N1C1=CC=CC=C1 ZYFVNVRFVHJEIU-UHFFFAOYSA-N 0.000 description 1
• 206010035148 Plague Diseases 0.000 description 1
• 208000007452 Plasmacytoma Diseases 0.000 description 1
• 206010035742 Pneumonitis Diseases 0.000 description 1
• 206010065857 Primary Effusion Lymphoma Diseases 0.000 description 1
• 206010036711 Primary mediastinal large B-cell lymphomas Diseases 0.000 description 1
• 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 1
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
• 239000013614 RNA sample Substances 0.000 description 1
• 238000011529 RT qPCR Methods 0.000 description 1
• 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 1
• 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
• 208000035415 Reinfection Diseases 0.000 description 1
• 241000219061 Rheum Species 0.000 description 1
• 206010039361 Sacroiliitis Diseases 0.000 description 1
• 208000034189 Sclerosis Diseases 0.000 description 1
• 108091081021 Sense strand Proteins 0.000 description 1
• 238000012300 Sequence Analysis Methods 0.000 description 1
• 208000019802 Sexually transmitted disease Diseases 0.000 description 1
• 208000032023 Signs and Symptoms Diseases 0.000 description 1
• 206010040943 Skin Ulcer Diseases 0.000 description 1
• 206010040867 Skin hypertrophy Diseases 0.000 description 1
• 206010041519 Spider naevus Diseases 0.000 description 1
• 208000007156 Spondylarthritis Diseases 0.000 description 1
• 241000191967 Staphylococcus aureus Species 0.000 description 1
• 102000019197 Superoxide Dismutase Human genes 0.000 description 1
• 108010012715 Superoxide dismutase Proteins 0.000 description 1
• 208000033809 Suppuration Diseases 0.000 description 1
• 201000009594 Systemic Scleroderma Diseases 0.000 description 1
• 206010042953 Systemic sclerosis Diseases 0.000 description 1
• 230000020385 T cell costimulation Effects 0.000 description 1
• 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 1
• 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 1
• 201000011176 T-cell adult acute lymphocytic leukemia Diseases 0.000 description 1
• 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
• 208000001871 Tachycardia Diseases 0.000 description 1
• QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
• 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
• 208000034841 Thrombotic Microangiopathies Diseases 0.000 description 1
• AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
• 101710183280 Topoisomerase Proteins 0.000 description 1
• 206010044245 Toxic optic neuropathy Diseases 0.000 description 1
• 241000159243 Toxicodendron radicans Species 0.000 description 1
• 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
• 241000209140 Triticum Species 0.000 description 1
• 235000021307 Triticum Nutrition 0.000 description 1
• 241000223109 Trypanosoma cruzi Species 0.000 description 1
• 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
• 208000025865 Ulcer Diseases 0.000 description 1
• 208000024780 Urticaria Diseases 0.000 description 1
• 206010046851 Uveitis Diseases 0.000 description 1
• 241000700647 Variola virus Species 0.000 description 1
• 102000013127 Vimentin Human genes 0.000 description 1
• 108010065472 Vimentin Proteins 0.000 description 1
• 208000034699 Vitreous floaters Diseases 0.000 description 1
• 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
• 241000607479 Yersinia pestis Species 0.000 description 1
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
• 229960004748 abacavir Drugs 0.000 description 1
• MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 description 1
• 229960003697 abatacept Drugs 0.000 description 1
• 206010000059 abdominal discomfort Diseases 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 229940119059 actemra Drugs 0.000 description 1
• 208000024716 acute asthma Diseases 0.000 description 1
• 208000036677 acute biphenotypic leukemia Diseases 0.000 description 1
• 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 1
• 208000005652 acute fatty liver of pregnancy Diseases 0.000 description 1
• 208000013593 acute megakaryoblastic leukemia Diseases 0.000 description 1
• 208000020700 acute megakaryocytic leukemia Diseases 0.000 description 1
• 230000033289 adaptive immune response Effects 0.000 description 1
• 210000002534 adenoid Anatomy 0.000 description 1
• 230000000145 adjuvantlike effect Effects 0.000 description 1
• 201000006966 adult T-cell leukemia Diseases 0.000 description 1
• 238000001261 affinity purification Methods 0.000 description 1
• 238000011256 aggressive treatment Methods 0.000 description 1
• 230000000961 alloantigen Effects 0.000 description 1
• DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
• 229960003805 amantadine Drugs 0.000 description 1
• 230000006229 amino acid addition Effects 0.000 description 1
• 210000004381 amniotic fluid Anatomy 0.000 description 1
• 229960004238 anakinra Drugs 0.000 description 1
• 230000036592 analgesia Effects 0.000 description 1
• 239000012491 analyte Substances 0.000 description 1
• 238000004873 anchoring Methods 0.000 description 1
• 206010002449 angioimmunoblastic T-cell lymphoma Diseases 0.000 description 1
• 208000022531 anorexia Diseases 0.000 description 1
• 239000005557 antagonist Substances 0.000 description 1
• 201000004612 anterior uveitis Diseases 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000001760 anti-analgesic effect Effects 0.000 description 1
• 230000003110 anti-inflammatory effect Effects 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 230000005875 antibody response Effects 0.000 description 1
• 239000000935 antidepressant agent Substances 0.000 description 1
• 229940005513 antidepressants Drugs 0.000 description 1
• 230000030741 antigen processing and presentation Effects 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 210000001742 aqueous humor Anatomy 0.000 description 1
• 238000000149 argon plasma sintering Methods 0.000 description 1
• 210000001188 articular cartilage Anatomy 0.000 description 1
• 238000007845 assembly PCR Methods 0.000 description 1
• 238000007846 asymmetric PCR Methods 0.000 description 1
• 208000010668 atopic eczema Diseases 0.000 description 1
• 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
• 208000027625 autoimmune inner ear disease Diseases 0.000 description 1
• 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
• 229940003504 avonex Drugs 0.000 description 1
• 210000000649 b-lymphocyte subset Anatomy 0.000 description 1
• 229960000794 baclofen Drugs 0.000 description 1
• 208000022362 bacterial infectious disease Diseases 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• 229940049706 benzodiazepine Drugs 0.000 description 1
• 229940021459 betaseron Drugs 0.000 description 1
• 230000002457 bidirectional effect Effects 0.000 description 1
• 210000000941 bile Anatomy 0.000 description 1
• 239000012620 biological material Substances 0.000 description 1
• 239000012472 biological sample Substances 0.000 description 1
• 210000004204 blood vessel Anatomy 0.000 description 1
• 231100000366 bone marrow toxicity Toxicity 0.000 description 1
• 230000006931 brain damage Effects 0.000 description 1
• 231100000874 brain damage Toxicity 0.000 description 1
• 208000029028 brain injury Diseases 0.000 description 1
• 210000005252 bulbus oculi Anatomy 0.000 description 1
• 208000000594 bullous pemphigoid Diseases 0.000 description 1
• 210000001217 buttock Anatomy 0.000 description 1
• 229940046731 calcineurin inhibitors Drugs 0.000 description 1
• 210000000845 cartilage Anatomy 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 230000020411 cell activation Effects 0.000 description 1
• 230000030833 cell death Effects 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 239000006285 cell suspension Substances 0.000 description 1
• 238000002659 cell therapy Methods 0.000 description 1
• 229940107810 cellcept Drugs 0.000 description 1
• 230000001413 cellular effect Effects 0.000 description 1
• 230000036755 cellular response Effects 0.000 description 1
• 210000000038 chest Anatomy 0.000 description 1
• 230000001713 cholinergic effect Effects 0.000 description 1
• 208000023819 chronic asthma Diseases 0.000 description 1
• 208000024207 chronic leukemia Diseases 0.000 description 1
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
• 208000023738 chronic lymphocytic leukemia/small lymphocytic lymphoma Diseases 0.000 description 1
• 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
• 201000009151 chronic rhinitis Diseases 0.000 description 1
• 231100000749 chronicity Toxicity 0.000 description 1
• 210000001268 chyle Anatomy 0.000 description 1
• 210000004913 chyme Anatomy 0.000 description 1
• 210000001072 colon Anatomy 0.000 description 1
• 230000021615 conjugation Effects 0.000 description 1
• 210000002808 connective tissue Anatomy 0.000 description 1
• 208000010247 contact dermatitis Diseases 0.000 description 1
• 238000011109 contamination Methods 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 229940038717 copaxone Drugs 0.000 description 1
• 229940111134 coxibs Drugs 0.000 description 1
• 201000005637 crescentic glomerulonephritis Diseases 0.000 description 1
• 108010061103 cyclic citrullinated peptide Proteins 0.000 description 1
• 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
• 229930182912 cyclosporin Natural products 0.000 description 1
• 230000002559 cytogenic effect Effects 0.000 description 1
• 230000009089 cytolysis Effects 0.000 description 1
• 230000003013 cytotoxicity Effects 0.000 description 1
• 231100000135 cytotoxicity Toxicity 0.000 description 1
• 230000002498 deadly effect Effects 0.000 description 1
• 238000012350 deep sequencing Methods 0.000 description 1
• 230000007812 deficiency Effects 0.000 description 1
• 238000000432 density-gradient centrifugation Methods 0.000 description 1
• 201000001981 dermatomyositis Diseases 0.000 description 1
• 238000007435 diagnostic evaluation Methods 0.000 description 1
• 238000010586 diagram Methods 0.000 description 1
• 230000009274 differential gene expression Effects 0.000 description 1
• 239000012470 diluted sample Substances 0.000 description 1
• XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
• 235000011180 diphosphates Nutrition 0.000 description 1
• NTGLQWGMESPVBV-UHFFFAOYSA-N diproqualone Chemical compound C1=CC=C2C(=O)N(CC(O)CO)C(C)=NC2=C1 NTGLQWGMESPVBV-UHFFFAOYSA-N 0.000 description 1
• 229950003185 diproqualone Drugs 0.000 description 1
• 238000002845 discoloration Methods 0.000 description 1
• 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
• 231100000676 disease causative agent Toxicity 0.000 description 1
• 230000005750 disease progression Effects 0.000 description 1
• ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 1
• 238000006073 displacement reaction Methods 0.000 description 1
• 208000002173 dizziness Diseases 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 208000029444 double vision Diseases 0.000 description 1
• 238000001647 drug administration Methods 0.000 description 1
• 201000005311 drug allergy Diseases 0.000 description 1
• 230000009977 dual effect Effects 0.000 description 1
• 230000008482 dysregulation Effects 0.000 description 1
• 239000012636 effector Substances 0.000 description 1
• 210000003162 effector t lymphocyte Anatomy 0.000 description 1
• 210000001513 elbow Anatomy 0.000 description 1
• 229940073621 enbrel Drugs 0.000 description 1
• 230000002708 enhancing effect Effects 0.000 description 1
• 208000037902 enteropathy Diseases 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 230000003628 erosive effect Effects 0.000 description 1
• 210000003238 esophagus Anatomy 0.000 description 1
• 230000000763 evoking effect Effects 0.000 description 1
• 238000007387 excisional biopsy Methods 0.000 description 1
• 230000001747 exhibiting effect Effects 0.000 description 1
• 210000003722 extracellular fluid Anatomy 0.000 description 1
• 208000027993 eye symptom Diseases 0.000 description 1
• 210000000887 face Anatomy 0.000 description 1
• 210000003608 fece Anatomy 0.000 description 1
• 210000003754 fetus Anatomy 0.000 description 1
• 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
• 230000003325 follicular Effects 0.000 description 1
• 210000000285 follicular dendritic cell Anatomy 0.000 description 1
• 238000009472 formulation Methods 0.000 description 1
• 108020001507 fusion proteins Proteins 0.000 description 1
• 102000037865 fusion proteins Human genes 0.000 description 1
• UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
• 238000002695 general anesthesia Methods 0.000 description 1
• 238000010353 genetic engineering Methods 0.000 description 1
• 210000004907 gland Anatomy 0.000 description 1
• 229960003776 glatiramer acetate Drugs 0.000 description 1
• 239000003862 glucocorticoid Substances 0.000 description 1
• 235000021312 gluten Nutrition 0.000 description 1
• 150000004676 glycans Chemical class 0.000 description 1
• 201000003872 goiter Diseases 0.000 description 1
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
• 229910052737 gold Inorganic materials 0.000 description 1
• 239000010931 gold Substances 0.000 description 1
• 210000004209 hair Anatomy 0.000 description 1
• 208000024963 hair loss Diseases 0.000 description 1
• 230000003676 hair loss Effects 0.000 description 1
• 201000009277 hairy cell leukemia Diseases 0.000 description 1
• 210000003128 head Anatomy 0.000 description 1
• 230000010370 hearing loss Effects 0.000 description 1
• 231100000888 hearing loss Toxicity 0.000 description 1
• 208000016354 hearing loss disease Diseases 0.000 description 1
• 208000025750 heavy chain disease Diseases 0.000 description 1
• 238000005534 hematocrit Methods 0.000 description 1
• 208000007475 hemolytic anemia Diseases 0.000 description 1
• 208000006454 hepatitis Diseases 0.000 description 1
• 231100000283 hepatitis Toxicity 0.000 description 1
• 206010066957 hepatosplenic T-cell lymphoma Diseases 0.000 description 1
• 231100000304 hepatotoxicity Toxicity 0.000 description 1
• 239000000833 heterodimer Substances 0.000 description 1
• 208000002557 hidradenitis Diseases 0.000 description 1
• 201000007162 hidradenitis suppurativa Diseases 0.000 description 1
• 238000012165 high-throughput sequencing Methods 0.000 description 1
• 238000007849 hot-start PCR Methods 0.000 description 1
• 210000005260 human cell Anatomy 0.000 description 1
• 235000020256 human milk Nutrition 0.000 description 1
• 210000004251 human milk Anatomy 0.000 description 1
• 239000010800 human waste Substances 0.000 description 1
• 229940048921 humira Drugs 0.000 description 1
• 208000034783 hypoesthesia Diseases 0.000 description 1
• 229960001680 ibuprofen Drugs 0.000 description 1
• 230000003100 immobilizing effect Effects 0.000 description 1
• 230000006450 immune cell response Effects 0.000 description 1
• 230000007233 immunological mechanism Effects 0.000 description 1
• 229940073062 imuran Drugs 0.000 description 1
• 238000007850 in situ PCR Methods 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 238000007386 incisional biopsy Methods 0.000 description 1
• 206010021654 increased appetite Diseases 0.000 description 1
• 229960000905 indomethacin Drugs 0.000 description 1
• 208000000509 infertility Diseases 0.000 description 1
• 230000036512 infertility Effects 0.000 description 1
• 231100000535 infertility Toxicity 0.000 description 1
• 210000004969 inflammatory cell Anatomy 0.000 description 1
• 230000006749 inflammatory damage Effects 0.000 description 1
• 208000027866 inflammatory disease Diseases 0.000 description 1
• 239000003112 inhibitor Substances 0.000 description 1
• 210000005007 innate immune system Anatomy 0.000 description 1
• 238000003780 insertion Methods 0.000 description 1
• 230000037431 insertion Effects 0.000 description 1
• 230000010354 integration Effects 0.000 description 1
• 229940047124 interferons Drugs 0.000 description 1
• 208000028774 intestinal disease Diseases 0.000 description 1
• 210000000936 intestine Anatomy 0.000 description 1
• 210000002977 intracellular fluid Anatomy 0.000 description 1
• 208000026876 intravascular large B-cell lymphoma Diseases 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• 230000002427 irreversible effect Effects 0.000 description 1
• 238000005304 joining Methods 0.000 description 1
• 230000000366 juvenile effect Effects 0.000 description 1
• 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
• 230000003907 kidney function Effects 0.000 description 1
• 229940054136 kineret Drugs 0.000 description 1
• 210000003127 knee Anatomy 0.000 description 1
• CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
• 229940078795 lactoferrin Drugs 0.000 description 1
• 235000021242 lactoferrin Nutrition 0.000 description 1
• 238000000370 laser capture micro-dissection Methods 0.000 description 1
• 150000002617 leukotrienes Chemical class 0.000 description 1
• 229960004194 lidocaine Drugs 0.000 description 1
• 238000007834 ligase chain reaction Methods 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 229940063721 lioresal Drugs 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• 208000019423 liver disease Diseases 0.000 description 1
• 238000007449 liver function test Methods 0.000 description 1
• 208000018883 loss of balance Diseases 0.000 description 1
• 208000030208 low-grade fever Diseases 0.000 description 1
• 238000005461 lubrication Methods 0.000 description 1
• 210000004705 lumbosacral region Anatomy 0.000 description 1
• 201000005202 lung cancer Diseases 0.000 description 1
• 208000020816 lung neoplasm Diseases 0.000 description 1
• 208000007282 lymphomatoid papulosis Diseases 0.000 description 1
• 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 description 1
• 201000000564 macroglobulinemia Diseases 0.000 description 1
• 210000002540 macrophage Anatomy 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 238000007898 magnetic cell sorting Methods 0.000 description 1
• 239000006249 magnetic particle Substances 0.000 description 1
• 206010025482 malaise Diseases 0.000 description 1
• 210000003794 male germ cell Anatomy 0.000 description 1
• 229940118019 malondialdehyde Drugs 0.000 description 1
• 210000003826 marginal zone b cell Anatomy 0.000 description 1
• 201000000638 mature B-cell neoplasm Diseases 0.000 description 1
• 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 description 1
• 210000004379 membrane Anatomy 0.000 description 1
• 239000012528 membrane Substances 0.000 description 1
• 210000001806 memory b lymphocyte Anatomy 0.000 description 1
• 210000003071 memory t lymphocyte Anatomy 0.000 description 1
• 210000004914 menses Anatomy 0.000 description 1
• 230000003340 mental effect Effects 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 230000001394 metastastic effect Effects 0.000 description 1
• 206010061289 metastatic neoplasm Diseases 0.000 description 1
• 229960003085 meticillin Drugs 0.000 description 1
• 239000002679 microRNA Substances 0.000 description 1
• 229960001156 mitoxantrone Drugs 0.000 description 1
• 230000037230 mobility Effects 0.000 description 1
• 238000010369 molecular cloning Methods 0.000 description 1
• 210000001616 monocyte Anatomy 0.000 description 1
• 230000036651 mood Effects 0.000 description 1
• 210000004400 mucous membrane Anatomy 0.000 description 1
• 210000003097 mucus Anatomy 0.000 description 1
• 229960003816 muromonab-cd3 Drugs 0.000 description 1
• 208000016334 muscle symptom Diseases 0.000 description 1
• 206010028417 myasthenia gravis Diseases 0.000 description 1
• 229940014456 mycophenolate Drugs 0.000 description 1
• RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
• 229960004866 mycophenolate mofetil Drugs 0.000 description 1
• HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
• 201000005962 mycosis fungoides Diseases 0.000 description 1
• 201000000050 myeloid neoplasm Diseases 0.000 description 1
• 229960002009 naproxen Drugs 0.000 description 1
• CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
• 229960005027 natalizumab Drugs 0.000 description 1
• 210000000822 natural killer cell Anatomy 0.000 description 1
• 208000010915 neoplasm of mature B-cells Diseases 0.000 description 1
• 208000021119 neoplasm of mature T-cells or NK-cells Diseases 0.000 description 1
• 230000009826 neoplastic cell growth Effects 0.000 description 1
• 201000008383 nephritis Diseases 0.000 description 1
• 231100000417 nephrotoxicity Toxicity 0.000 description 1
• 230000008764 nerve damage Effects 0.000 description 1
• 210000000653 nervous system Anatomy 0.000 description 1
• 238000007857 nested PCR Methods 0.000 description 1
• 230000004770 neurodegeneration Effects 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• 210000000440 neutrophil Anatomy 0.000 description 1
• 238000011457 non-pharmacological treatment Methods 0.000 description 1
• 238000010899 nucleation Methods 0.000 description 1
• 239000002853 nucleic acid probe Substances 0.000 description 1
• 201000010854 nut allergy Diseases 0.000 description 1
• 235000020824 obesity Nutrition 0.000 description 1
• 238000001584 occupational therapy Methods 0.000 description 1
• 231100000327 ocular toxicity Toxicity 0.000 description 1
• 229940127240 opiate Drugs 0.000 description 1
• 239000000014 opioid analgesic Substances 0.000 description 1
• 229940005483 opioid analgesics Drugs 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 229940035567 orencia Drugs 0.000 description 1
• 229940046781 other immunosuppressants in atc Drugs 0.000 description 1
• 210000001672 ovary Anatomy 0.000 description 1
• 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
• 239000005022 packaging material Substances 0.000 description 1
• 230000000242 pagocytic effect Effects 0.000 description 1
• 210000002741 palatine tonsil Anatomy 0.000 description 1
• 206010033675 panniculitis Diseases 0.000 description 1
• 208000035824 paresthesia Diseases 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 230000009054 pathological process Effects 0.000 description 1
• 201000001976 pemphigus vulgaris Diseases 0.000 description 1
• 210000003516 pericardium Anatomy 0.000 description 1
• JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
• 229960002895 phenylbutazone Drugs 0.000 description 1
• VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
• 210000004214 philadelphia chromosome Anatomy 0.000 description 1
• 208000026435 phlegm Diseases 0.000 description 1
• 150000003904 phospholipids Chemical class 0.000 description 1
• 238000000554 physical therapy Methods 0.000 description 1
• 230000004962 physiological condition Effects 0.000 description 1
• 210000002826 placenta Anatomy 0.000 description 1
• 208000010626 plasma cell neoplasm Diseases 0.000 description 1
• 210000004180 plasmocyte Anatomy 0.000 description 1
• 210000004224 pleura Anatomy 0.000 description 1
• 210000004910 pleural fluid Anatomy 0.000 description 1
• 229920000642 polymer Polymers 0.000 description 1
• 229920001282 polysaccharide Polymers 0.000 description 1
• 239000005017 polysaccharide Substances 0.000 description 1
• 201000011461 pre-eclampsia Diseases 0.000 description 1
• 229960004618 prednisone Drugs 0.000 description 1
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 208000000814 primary cutaneous anaplastic large cell lymphoma Diseases 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 208000037821 progressive disease Diseases 0.000 description 1
• 150000003180 prostaglandins Chemical class 0.000 description 1
• 230000001823 pruritic effect Effects 0.000 description 1
• 208000020016 psychiatric disease Diseases 0.000 description 1
• 208000005069 pulmonary fibrosis Diseases 0.000 description 1
• 238000000746 purification Methods 0.000 description 1
• 210000004915 pus Anatomy 0.000 description 1
• 238000012175 pyrosequencing Methods 0.000 description 1
• 238000003908 quality control method Methods 0.000 description 1
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
• 230000004461 rapid eye movement Effects 0.000 description 1
• 238000011867 re-evaluation Methods 0.000 description 1
• 239000011535 reaction buffer Substances 0.000 description 1
• 239000011541 reaction mixture Substances 0.000 description 1
• 229940038850 rebif Drugs 0.000 description 1
• 230000007115 recruitment Effects 0.000 description 1
• 230000000306 recurrent effect Effects 0.000 description 1
• 210000003289 regulatory T cell Anatomy 0.000 description 1
• 229940116176 remicade Drugs 0.000 description 1
• 238000009877 rendering Methods 0.000 description 1
• 238000003757 reverse transcription PCR Methods 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 206010039083 rhinitis Diseases 0.000 description 1
• 239000003161 ribonuclease inhibitor Substances 0.000 description 1
• 230000000630 rising effect Effects 0.000 description 1
• 238000005096 rolling process Methods 0.000 description 1
• 210000004918 root sheath Anatomy 0.000 description 1
• 238000009666 routine test Methods 0.000 description 1
• 210000003296 saliva Anatomy 0.000 description 1
• 150000003839 salts Chemical class 0.000 description 1
• 210000003786 sclera Anatomy 0.000 description 1
• 238000010845 search algorithm Methods 0.000 description 1
• 210000002374 sebum Anatomy 0.000 description 1
• 230000003248 secreting effect Effects 0.000 description 1
• 210000000582 semen Anatomy 0.000 description 1
• 230000035807 sensation Effects 0.000 description 1
• 235000019615 sensations Nutrition 0.000 description 1
• 230000000405 serological effect Effects 0.000 description 1
• 238000009589 serological test Methods 0.000 description 1
• 210000002966 serum Anatomy 0.000 description 1
• 206010040560 shock Diseases 0.000 description 1
• 208000013220 shortness of breath Diseases 0.000 description 1
• 229960002930 sirolimus Drugs 0.000 description 1
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
• 238000007390 skin biopsy Methods 0.000 description 1
• 210000004927 skin cell Anatomy 0.000 description 1
• 231100000019 skin ulcer Toxicity 0.000 description 1
• 210000000813 small intestine Anatomy 0.000 description 1
• 229940126586 small molecule drug Drugs 0.000 description 1
• 230000035943 smell Effects 0.000 description 1
• 239000002904 solvent Substances 0.000 description 1
• 238000001179 sorption measurement Methods 0.000 description 1
• 238000011895 specific detection Methods 0.000 description 1
• 210000000952 spleen Anatomy 0.000 description 1
• 206010062113 splenic marginal zone lymphoma Diseases 0.000 description 1
• 210000000130 stem cell Anatomy 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• 210000004304 subcutaneous tissue Anatomy 0.000 description 1
• 238000006467 substitution reaction Methods 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• 230000009747 swallowing Effects 0.000 description 1
• 210000004243 sweat Anatomy 0.000 description 1
• 230000035900 sweating Effects 0.000 description 1
• 230000008961 swelling Effects 0.000 description 1
• 230000009897 systematic effect Effects 0.000 description 1
• 229940037128 systemic glucocorticoids Drugs 0.000 description 1
• 230000006794 tachycardia Effects 0.000 description 1
• 229960001967 tacrolimus Drugs 0.000 description 1
• QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
• 235000019640 taste Nutrition 0.000 description 1
• 210000001138 tear Anatomy 0.000 description 1
• 210000001550 testis Anatomy 0.000 description 1
• 230000035922 thirst Effects 0.000 description 1
• 229940034208 thyroxine Drugs 0.000 description 1
• XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
• 229960000488 tizanidine Drugs 0.000 description 1
• 229960003989 tocilizumab Drugs 0.000 description 1
• 238000003325 tomography Methods 0.000 description 1
• 210000000515 tooth Anatomy 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 238000007862 touchdown PCR Methods 0.000 description 1
• 238000012549 training Methods 0.000 description 1
• 238000011277 treatment modality Methods 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• 201000008827 tuberculosis Diseases 0.000 description 1
• 239000000107 tumor biomarker Substances 0.000 description 1
• 230000005951 type IV hypersensitivity Effects 0.000 description 1
• 231100000397 ulcer Toxicity 0.000 description 1
• 241000712461 unidentified influenza virus Species 0.000 description 1
• 210000000689 upper leg Anatomy 0.000 description 1
• 230000002485 urinary effect Effects 0.000 description 1
• 210000004291 uterus Anatomy 0.000 description 1
• 210000005048 vimentin Anatomy 0.000 description 1
• 239000013603 viral vector Substances 0.000 description 1
• 210000004916 vomit Anatomy 0.000 description 1
• 229940000119 zanaflex Drugs 0.000 description 1